Updated: Drug-Drug Interaction Guide: From HIV Prevention to Treatment

Updated by lead author Dr. John J. Faragon, with the Medical Care Criteria Committee (MCCC), the Drug-Drug Interaction Guide: From HIV Prevention to Treatment was developed to provide clinicians with evidence-based guidance on drug-drug interactions involving antiretroviral medications for the prevention and treatment of HIV.

Updates to this resource include:

• Identifying Drug-Drug Interactions > Risks of Concomitant Drug Use section: Updated discussion of potent inducers
• Drug-Drug Interactions by Antiviral Medication Class section: Updated information on lenacapavir (LEN) interactions to specify when used for HIV treatment (see Table 19A) and when used for HIV prevention (see Table 19B)
• Drug-Drug Interactions by Common Medication Class section: Updated tables with information on LEN interactions when used for HIV prevention:
• Table 30: Inhaled and Injected Corticosteroids
• Table 35: Anticonvulsants
• Table 45: Rifamycins and Other Antituberculosis Medications

Contents:

• Purpose of This Guide
• Identifying Drug-Drug Interactions
• Classifications and Mechanisms of Drug-Drug Interactions

• Drug-Drug Interactions by Antiretroviral Medication Class
• Drug-Drug Interactions by Common Medication Class
• Printable PDF

Go to full guide

Hot Topics

• NYSDOH: Announcing PrEP Aware Week: October 19-25, 2025
• CEI: Syphilis in Pregnancy Toolkit Now Available
• CEI: New Online Accredited Courses & Learning Modules
• NASC: Research Study to Better Understand Perception of Integrated HIV and Opioid Use Disorder in Local Practice Setting
• HIVinfo: Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV
• HIVinfo: Update to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

See all Hot Topics

Save the Date

PrEP Aware Week 2025

Learn more at prepforsex.org



Medical Cannabis Symposium 2025

Learn more at 2nd Annual NYS Medical Cannabis Symposium: Cannabinoids in Clinical Practice

Don't Miss

Updated: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults

Updated: Second-Line ART After Treatment Failure or for Regimen Simplification

Updated: Prevention and Treatment of Mpox

Case 6. Is More Really More? Optimizing Options for a Healthy Patient: Healthy 48-year-old man with HIV for 15 years, stable viral suppression, looking to optimize health—diet, exercise, immune-boosting supplements, safest HIV and HTN meds. Listen as Chris and Eileen discuss their approach to giving patients the good news about their health, health maintenance, supplement use, and whether to stay the course or switch ART regimens in patients who are doing well. Listen Now

Case 7. Newer Kids on the Block: Use of Novel ARVs for Multidrug Resistance: How to formulate an effective ART regimen acceptable to a 56-year-old man, with unsuppressed HIV, 20+ year ART history, extensive drug resistance, and adherence challenges? Listen as Eileen and Chris interpret resistance testing results, discuss barriers to treatment and adherence for this patient, and evaluate the possibility of using one of the novel agents—fostemsavir, ibalizumab, and lenacapavir. What would you do? Listen Now

Coming Soon

Case 8. Charting a Path Forward: Subspecialists request simplified ART for a 56-year-old woman with a long ART history, who is taking a DOAC, has evolving renal function, and some drug resistance. Which factors to prioritize? Eileen and Chris have some, but not a complete, medical history. Listen as they work through the information they do have, consider 7 questions key in making an ART switch, and evaluate the available options. Listen October 14

Case 9. A New TRIO to Reduce ART Complexity: A 62-year-old patient with HIV for ~40 years presents on the life-saving TRIO regimen after a beloved care provider retires. Will a switch improve his quality of life? Eileen and Chris suspect that a change to a once-a-day regimen with fewer pills will maintain his viral suppression and make life easier, but the TRIO regimen inspires dedication in many long-term patients. Would he be open to a switch? Would it confer other benefits? Listen as Eileen and Chris consider the necessity of switch and plot a treatment course. Listen October 28

Insights from the 13th International AIDS Society Conference on HIV Science: In this episode of Conversations with CEI, Dr. Steven Fine unpacks some of the latest developments and research presented at the 2025 International AIDS Society (IAS) Conference on HIV Science, held in Kigali, Rwanda. From innovative treatment strategies to advancements in prevention and global health equity, Dr. Fine highlights the pivotal discussions and groundbreaking studies that are shaping the future of HIV care. Tune in to gain a deeper understanding of the strides being made in the fight against HIV and the collaborative efforts driving progress on a global scale. Listen Now

CEI:

• 10/14: HIV Remission and Cure: What Have We Learned, and What Are We Still Missing?
• 10/15: This Month in HIV: Cancer Screening and HIV
• 10/22: Extended-Release Buprenorphine for Opioid Use Disorder

See all

General:

• 10/19: NYSDOH AI: 2025 PrEP Aware Week
• 10/19: IDWeek 2025
• 10/29: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Clinical & Non-Clinical Providers
• 11/1: National Conference on Correctional Health Care
• 11/6: ANAC2025
• 11/7: 2nd Annual NYS Medical Cannabis Symposium: Cannabinoids in Clinical Practice
• 11/18: The Union World Conference on Lung Health 2025
• 12/6: ISAM Americas Summit – 2025 Annual Conference
• 12/14: 2025 Ryan White HIV/AIDS Program Clinical Conference
• 2/22/2026: CROI 2026
• 4/23/2026: ASAM 57th Annual Conference: Innovations in Addiction Medicine and Science
• 4/30/2026: ACTHIV 2026
• 7/25/2026: AIDS 2026, the 26th International AIDS Conference
• 11/8/2026: WPATH 2026

See all